OraSure Technologies, Inc. (OSUR)

NMS – Цена в реальном времени. Валюта: USD

4.46

+0.05 (1.13%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

4.41

-0.05 (-1.12%)

После закрытия: Jun 26, 2026, 7:07 PM EDT

11.06.2026

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.

07.05.2026

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

06.05.2026

OraSure Announces First Quarter 2026 Financial Results

BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.

22.04.2026

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.

17.04.2026

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.

17.03.2026

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight.

17.03.2026

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure.

Видео

No Data

There is no data to display

Пресс-релизы

11.06.2026

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

06.05.2026

OraSure Announces First Quarter 2026 Financial Results

17.04.2026

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

17.03.2026

OraSure Technologies, Inc. (OSUR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

OraSure Technologies, Inc. (OSUR)

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Announces First Quarter 2026 Financial Results

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

Видео

No Data

Пресс-релизы

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Announces First Quarter 2026 Financial Results

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Announces First Quarter 2026 Financial Results

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

Видео

No Data

Пресс-релизы

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Announces First Quarter 2026 Financial Results

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Search stocks

OraSure Technologies, Inc. (OSUR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

OraSure Technologies, Inc. (OSUR)

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Announces First Quarter 2026 Financial Results

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

Видео

No Data

Пресс-релизы

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Announces First Quarter 2026 Financial Results

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Announces First Quarter 2026 Financial Results

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

Видео

No Data

Пресс-релизы

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Announces First Quarter 2026 Financial Results

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital